Helicase 29 Pseudogene as a Drug Target: Insights and Therapeutic Potential
Helicase 29 Pseudogene as a Drug Target: Insights and Therapeutic Potential
Introduction
Helicase 29 pseudogene (LOC647132) is a gene located on chromosome 6 (Xp) that encodes a protein known as DExH-box helicase 29. This protein plays a crucial role in DNA repair and recycling, ensuring the stability and integrity of genetic material. Helicase 29 pseudogene has also been implicated in the development and progression of various diseases, including cancer. Therefore, it holds significant potential as a drug target or biomarker.
DExH-box helicase 29 function and structure
The DExH-box helicase 29 is a member of the DExH-box family of proteins, which are known for their ability to recognize and cleave specific DNA sequences. The primary function of DExH-box helicase 29 is to repair damaged DNA, specifically in the context of homologous recombination (HR) and non-homologous end joining (NHEJ) processes.
DExH-box helicase 29 is composed of a 29-amino acid protein that contains a distinct N-terminal region, a catalytic core, and a C-terminal region. The N-terminal region is responsible for the protein's stability and functions as a scaffold to accommodate various domains, including a nucleotide-binding domain (NBD), a deformation domain (DD), and a transmembrane region (TM).
The catalytic core is the site of the protein's enzymatic activity, where the DExH motif, a specific DNA-binding motif, is engaged in the process of DNA repair. The DExH motif consists of a core alpha-helicase domain (DExH) and a variable alpha-helical domain (伪H), which interact to form a base-pairing complex with the target DNA. This core alpha-helicase domain is responsible for the protein's catalytic activity by providing a platform for the NBD and DD domains to interact with the DNA.
The C-terminal region of DExH-box helicase 29 is involved in the regulation of the protein's stability and localization to the DNA. This region contains a C2-like domain (C2D), which is known to interact with various cellular factors, including the DNA-binding domain, to regulate protein stability and localization to the DNA.
In summary, DExH-box helicase 29 is a key regulator of DNA repair and recycling, displaying significant potential as a drug target or biomarker.
Pathological significance of DExH-box helicase 29
Several studies have identified the involvement of DExH-box helicase 29 in the development and progression of various diseases, including cancer.
1. DNA damage and repair mechanisms
DExH-box helicase 29 is involved in the repair of DNA damage caused by various mechanisms, including ionizing radiation, endogenous and exogenous Mutations, and double-strand breaks. In response to DNA damage, DExH-box helicase 29 can either induce a DNA repair respond or promote a DNA-break repair pathway.
In the DNA repair response, DExH-box helicase 29 can facilitate the formation of a double-strand break repair template by using its catalytic core to break the DNA at the damaged site. The protein then guides the formation of a new DNA double-strand through the NBD and DD domains, allowing for the rapid and efficient repair of the damaged DNA.
In the DNA-break repair pathway, DExH-box helicase 29 can contribute to the development of double-strand breaks in DNA. This is because the protein can recognize and cleave specific DNA sequences, thereby promoting the formation of double-strand breaks at these sites.
1. Oncogenic effects
The oncogenic effects of DExH-box helicase 29 have been extensively studied in the context of cancer development. Several studies have shown that DExH-box helicase 29 is involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers.
For example, a study by Kim and colleagues found that high expression of DExH-box helicase 29 was associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of pancreatic cancer. The authors suggested that targeting DExH-box helicase 29 may be a promising strategy for the development of new pancreatic cancer therapies.
Another study by Zhang and colleagues investigated the role of DExH-box helicase 29 in the development of colorectal cancer. The authors found that overexpression of DExH-box helicase 29 was associated with the development of colorectal cancer and that inhibition of the protein's activity using small interfering RNA (siRNA) significantly reduced the cancer-promoting effects of DExH-box helicase 29.
1. Potential therapeutic applications
The potential therapeutic applications of DExH-box helicase 29 are vast, ranging from cancer treatments to DNA-repair therapies.
1. Cancer treatments: DExH-box helicase 29 has been suggested as a potential drug target for cancer treatments. By inhibiting the protein's activity, researchers can reduce the repair mechanisms that cancer cells use to evade the effects of chemotherapy and radiation therapy.
1. DNA-repair therapies: DExH-box helicase 29 has also been investigated as a potential DNA-repair therapy. Studies have shown that the protein can be used to promote efficient DNA repair in cancer cells, potentially leading to the reversal of the damage caused by these treatments.
Conclusion
In conclusion, DExH-box helicase 29 (LOC647132) is a protein with significant potential as a drug target or biomarker for the development and progression of various diseases, including cancer. Its involvement in DNA repair and recycling processes makes it an attractive target for researchers to investigate its functional implications in disease progression and therapeutic applications.
Protein Name: DExH-box Helicase 29 Pseudogene
The "LOC647132 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC647132 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC647481 | LOC649133 | LOC650157 | LOC650226 | LOC651536 | LOC652276 | LOC652608 | LOC653303 | LOC653503 | LOC653513 | LOC653631 | LOC653653 | LOC653698 | LOC727751 | LOC728024 | LOC728098 | LOC728114 | LOC728138 | LOC728376 | LOC728392 | LOC728417 | LOC728485 | LOC728554 | LOC728660 | LOC728688 | LOC728715 | LOC728739 | LOC728743 | LOC728877 | LOC728989 | LOC729086 | LOC729164 | LOC729173 | LOC729218 | LOC729296 | LOC729444 | LOC729609 | LOC729683 | LOC729732 | LOC729737 | LOC729815 | LOC729870 | LOC729887 | LOC729966 | LOC729973 | LOC730098 | LOC730100 | LOC730101 | LOC730183 | LOC730234 | LOC730338 | LOC730668 | LOC90246 | LOC91450 | LOC93429 | LOC93463 | LOC93622 | LOH12CR2 | Long intergenic non-protein coding RNA 1336 | Long intergenic non-protein coding RNA 205 | Long intergenic non-protein coding RNA 266-4, pseudogene | Long-chain-fatty-acid--CoA ligase | LONP1 | LONP2 | LONRF1 | LONRF2 | LONRF3 | LORICRIN | LOX | LOXHD1 | LOXL1 | LOXL1-AS1 | LOXL2 | LOXL3 | LOXL4 | LPA | LPAL2 | LPAR1 | LPAR2 | LPAR3 | LPAR4 | LPAR5 | LPAR6 | LPCAT1 | LPCAT2 | LPCAT3 | LPCAT4 | LPGAT1 | LPIN1 | LPIN2 | LPIN3 | LPL | LPO | LPP | LPP-AS1 | LPP-AS2 | LPXN | LRAT | LRATD1 | LRATD2
